New hope for tough breast cancer: testing a powerful drug duo

This study is testing whether adding a new two-drug immunotherapy (iparomlimab and tuvonralimab) to standard platinum chemotherapy works better than chemotherapy alone for advanced triple-negative breast cancer that has worsened after one or two prior treatments. It will involve 78 participants who will be randomly assigned to receive either the new combination or just chemotherapy. The main goal is to see if the new combination can keep the cancer from growing for a longer period of time.